title: [Precocious puberty and polycystic ovarian syndrome: apropos of 13 cases].
abstract: BACKGROUND
  Precocious puberty and polycystic ovarian syndrome are two different entities which appear at different stages of ovarian development. Their association is uncommon.
  
  
  METHODS
  Thirteen girls presented idiopathic central precocious puberty with sexual development before the age of 8 years; menstruations were seen at the age of 9.5 years in one patient. Nine of them were given medroxyprogesterone or cyproterone acetate and two patients LHRH analog. Menarche occurred at a mean age of 11.8 +/- 1.5 years. After a mean free interval of 22 months, these thirteen patients developed hirsutism with irregular menstruations (eight patients) and weight gain (seven patients). The diagnosis of polycystic ovarian syndrome was confirmed by increased plasma testosterone (mean 91.1 +/- 14 ng/dl) and LH levels during LHRH test and by ultrasonography or coelioscopy. The treatment included cyproterone acetate plus 17 beta oestradiol; it was discontinued in eleven cases after 2 years of treatment. Plasma testosterone levels were normal 6 months later in association with regular menstruations. But three patients presented clinical and hormonal recurrence one year later, requiring repeated treatment.
  
  
  CONCLUSIONS
  This association seems to be related to the same gonadotropin dysfunction. It is necessary to regularly follow patients treated for precocious puberty.
authors.affiliation: Service de pédiatrie, CHU Purpan, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Pienkowski
authors.forename: M T
authors.initials: MT
authors.lastname: Tauber
authors.forename: P
authors.initials: P
authors.lastname: Pigeon
authors.forename: I
authors.initials: I
authors.lastname: Oliver
authors.forename: P
authors.initials: P
authors.lastname: Rochiccioli
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D002648:Child; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D011629:Puberty, Precocious / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D013739:Testosterone; D017373:Cyproterone Acetate; D004958:Estradiol; D017258:Medroxyprogesterone Acetate